Categories: News

Yidu Tech Announces Annual Results for Fiscal Year 2022

HONG KONG, June 27, 2022 /PRNewswire/ — Yidu Tech Inc. (“Yidu Tech”, the “Group”, HKEx: 2158), a leading company in China’s healthcare intelligence industry, announced its annual results for the fiscal year ended March 31, 2022 (“FY2022” or the “Reporting Period”). During the Reporting Period, the Group’s overall revenue continued to improve, with total revenue reaching RMB1,237 million, up 42.7% year-on-year (“YoY”), and gross profit increasing 22.0% YoY to RMB399 million.

Achieving synergies among the three business segments

Since the fiscal year 2019, the three business segments of Yidu Tech have maintained rapid growth for three consecutive years.

The Big Data Platform and Solutions segment continued to grow during the Reporting Period, with revenue up by 10.7% YoY to RMB445 million with a gross margin of 43.3%. As of March 31, 2022, Yidu Tech provided data intelligence platforms and data analytics-driven solutions to 82 leading research hospitals and 26 regulators and policy makers in China.

The Life Sciences Solutions segment maintained strong growth, with revenue reaching RMB359 million, a significant increase of 95.0% YoY, and a gross margin of 24.7%. During the Reporting Period, the number of active clients grew to 141, and the revenue retention of the core pharmaceutical, biotech, and medical device clients was 130%.

The Health Management Platform and Solutions segment grew significantly in FY2022, with revenue amounting to RMB425 million, up 68.5% YoY, and a gross margin of 27.7%. During the Reporting Period, the Group continued to increase its market penetration of the “Hui Min Bao” business and has served 1 province and 9 cities, for a total of 22 cities. At the end of the Reporting Period, the number of active users who completed at least one transaction on Yidu Tech’s health management platform reached 12 million.

According to the “14th Five-Year Plan”, China’s digital economy is expected to account for 10% of GDP in 2025. According to the Frost & Sullivan Report, the market size of China’s healthcare intelligence industry is expected to exceed RMB1.1 trillion in 2030. Overall, the healthcare intelligence industry has a vast growth potential.

Ms. Gong Yingying (Rujing), Chairlady, CEO and Founder of Yidu Tech, remarked, “Going forward, Yidu Tech will adhere to its mission of making value-based precision healthcare accessible to everyone and strengthen its core technology capabilities and ability to cultivate the healthcare ecosystem, thereby creating long-term value for the healthcare intelligence industry.”

View original content:https://www.prnewswire.com/news-releases/yidu-tech-announces-annual-results-for-fiscal-year-2022-301575479.html

SOURCE Yidu Tech

Staff

Recent Posts

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for…

15 hours ago

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research…

15 hours ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details –…

15 hours ago

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Prescription NAD+ Injection Access, At-Home Administration Models, Compounding Standards, and What Consumers Should Know Before…

15 hours ago

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

2 days ago